Literature DB >> 22189802

Comparative analysis of two methodologies for the identification of urinary red blood cell casts.

Carmen Antonia Sanches Ito1, Roberto Pecoits-Filho, Larissa Bail, Mônica Arcoverde Wosiack, Danieli Afinovicz, Aline Borsato Hauser.   

Abstract

INTRODUCTION: Dysmorphic red blood cells (RBCs) in the urine are a strong indicator of a glomerular bleeding source. RBC casts, which while generally following RBC dysmorphism are not frequently seen on routine urinalysis, are also important indicators of glomerular hematuria.
OBJECTIVE: This study tested the superiority of a urine concentration technique (CT) over the standard method (SM) for RBC cast identification in a group of patients suspected of glomerular hematuria.
MATERIAL AND METHODS: Of a total of 4,227 routine urinary samples, 249 with dysmorphic hematuria were selected. The samples were processed according to two techniques: standard method (SM) and concentration technique (CT). The percentages of RBC cast identification according to each method were compared.
RESULTS: The CT showed a higher rate of RBC casts (52.6%) compared to the SM (8.4%) (p < 0.001). DISCUSSION AND
CONCLUSION: We suggest that the SM did not sufficiently concentrate the urine sample, the RBC casts remaining in the supernatant and being discarded. The CT increased the sensitivity of the RBC cast yield. The CT, associated with the presence of RBC dysmorphism, was useful to increase the agreement of the two parameters used for identification of glomerular-based bleeding and the diagnosis of glomerular diseases, important causes of chronic kidney disease.

Entities:  

Mesh:

Year:  2011        PMID: 22189802

Source DB:  PubMed          Journal:  J Bras Nefrol        ISSN: 0101-2800


  1 in total

1.  Enhancing the Detection of Dysmorphic Red Blood Cells and Renal Tubular Epithelial Cells with a Modified Urinalysis Protocol.

Authors:  Yu Chu-Su; Kenichi Shukuya; Takashi Yokoyama; Wei-Chou Lin; Chih-Kang Chiang; Chii-Wann Lin
Journal:  Sci Rep       Date:  2017-01-11       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.